Document is current
Any future updates will be listed below
-
Authors
Killelea, Brigid K.
Herrin, Jeph
Soulos, Pamela R.
Pollack, Craig E.
Forman, Howard P.
Yu, James
Xu, Xiao
Tannenbaum, Sara
Wang, Shi-Yi
Gross, Cary P.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA190017)
- License Information
-
More Information
Article History
Received: 1 September 2019
Accepted: 21 November 2019
First Online: 2 December 2019
Compliance with ethical standards
:
: The authors do not have any financial relationship with the organization that funded the research. The authors report the following disclosures: Brigid Killelea has received honorarium for participation on an advisory board for Genentech. James Yu is a consultant for Augmenix. Xiao Xu has worked with CMS to develop and maintain performance measures. Pamela Soulos has received research funding from 21st Century Oncology. Howard Forman has no conflicts of interest to disclose. Shiyi Wang has no conflicts of interest to disclose. Craig Pollack owns stock with Gilead Pharmaceuticals. Cary Gross has received grant funding from NCCN and Johnson and Johnson. Jeph Herrin, has no conflicts of interest to disclose.
: This article does not contain any studies with human participants or animals performed by any of the authors.
